<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928707</url>
  </required_header>
  <id_info>
    <org_study_id>DSC/08/2357/38</org_study_id>
    <nct_id>NCT00928707</nct_id>
  </id_info>
  <brief_title>Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera</brief_title>
  <acronym>PV</acronym>
  <official_title>Phase II Study of the Histone-deacetylase Inhibitor GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Patients With JAK2V617F Positive Polycythemia Vera Non-responder to Hydroxyurea Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in
      combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia
      Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3
      months.

      Recruited patients will be randomly assigned to one of the following treatment groups:

        -  group A: 50 mg o.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum
           tolerated dose of hydroxyurea monotherapy already in use before admission to the study;

        -  group B: 50 mg b.i.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum
           tolerated dose of hydroxyurea monotherapy already in use before admission to the study.

      The two groups will be balanced for number and for Centre in order to provide valuable
      information on both treatment regimens.

      In both groups assigned doses shall remain stable until week 12, which is when the primary
      endpoint is assessed, unless specific tolerability issues arise which impose dose reduction.

      After the primary endpoint assessment at week 12, one of the following treatment schedules
      will be chosen case by case on the basis of the achieved clinical response and continued for
      up to 12 further weeks:

        -  Partial or Complete Response at week 12:

        -  group A: continue 50 mg o.d.;

        -  group B: continue 50 mg b.i.d.;

        -  No Response at week 12:

        -  group A: increase to 50 mg b.i.d.;

        -  group B: increase to 50 mg t.i.d.. At any time during study course, if toxicity is
           observed, GIVINOSTAT (ITF2357) treatment will be discontinued until recovery and then
           restarted at a reduced dose level. The drug will be definitively withdrawn in case of
           reappearance of toxicity even at a reduced daily dose. Overall, the treatment will last
           up to a maximum of 24 cumulative weeks of drug administration.

      The study will recruit subjects of both genders with an established diagnosis of JAK2V617F
      positive Polycythemia Vera according to the revised WHO criteria, in need of cytoreductive
      therapy, non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least
      3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy.</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of GIVINOSTAT-HU combination in patients with JAK2V617F positive PV NR to the MTD of HU monotherapy; to evaluate the molecular response.</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>GIVINOSTAT + MTD Hydroxyurea_1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIVINOSTAT + MTD Hydroxyurea_2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg b.i.d. of GIVINOSTAT + MTD of HU monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea</intervention_name>
    <description>50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy</description>
    <arm_group_label>GIVINOSTAT + MTD Hydroxyurea_1</arm_group_label>
    <other_name>GIVINOSTAT (ITF2357)</other_name>
    <other_name>ONCOCARBIDE (HYDROXYUREA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea</intervention_name>
    <description>50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy</description>
    <arm_group_label>GIVINOSTAT + MTD Hydroxyurea_2</arm_group_label>
    <other_name>GIVINOSTAT (ITF2357)</other_name>
    <other_name>ONCOCARBIDE (HYDROXYUREA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed Consent.

          -  Age ≥18 years.

          -  Confirmed diagnosis of Polycythemia Vera according to the revised WHO criteria.

          -  JAK2V617F positivity.

          -  Non-response to the maximum tolerated dose of hydroxyurea monotherapy for at least 3
             months.

          -  ECOG performance status &lt;3.

          -  Use of an effective means of contraception for women of childbearing potential and men
             with partners of childbearing potential.

          -  Willingness and capability to comply with the requirements of the study.

        Exclusion Criteria:

          -  Active bacterial or mycotic infection requiring antimicrobial treatment.

          -  Pregnancy or lactation.

          -  A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a
             QTc interval &gt; 450 ms, according to Bazett's correction formula).

          -  Use of concomitant medications that prolong the QT/QTc interval.

          -  Clinically significant cardiovascular disease including:

               -  Uncontrolled hypertension, myocardial infarction, unstable angin,within 6 months
                  from study start; ;

               -  New York Heart Association (NYHA) Grade II or greater congestive heart failure;

               -  History of any cardiac arrhythmia requiring medication (irrespective of its
                  severity);

               -  A history of additional risk factors for TdP (e.g., heart failure, hypokalemia,
                  family history of Long QT Syndrome).

          -  Positive blood test for HIV.

          -  Active HBV and/or HCV infection.

          -  Platelets count &lt;100x109/L within 14 days before enrolment.

          -  Absolute neutrophil count &lt;1.2x109/L within 14 days before enrolment.

          -  Serum creatinine &gt;2xULN.

          -  Total serum bilirubin &gt;1.5xULN.

          -  Serum AST/ALT &gt; 3xULN.

          -  History of other diseases, metabolic dysfunctions, physical examination findings, or
             clinical laboratory findings giving reasonable suspicion of a disease or condition
             that contraindicates use of an investigational drug or that might affect
             interpretation of the results of the study or render the subject at high risk from
             treatment complications.

          -  Interferon alpha within 14 days before enrolment.

          -  Anagrelide within 7 days before enrolment.

          -  Any other investigational drug within 28 days before enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Croce e Carle di Cuneo</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I. R. C. C. S. - Casa sollievo della sofferenza di San Giovanni Rotondo</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi di Firenze</name>
      <address>
        <city>Florence</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico &quot;Gaetano Martino&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti &quot;Villa Sofia - Cervello&quot; di Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale di Pescara, Presidio Ospedaliero &quot;Spirito Santo&quot;</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria della Misericordia di Perugia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale San Carlo di Potenza</name>
      <address>
        <city>Potenza</city>
        <state>PT</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio di Calabria</city>
        <state>RC</state>
        <zip>891225</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria S. Luigi Gonzaga di Orbassano</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Giovanni Battista(&quot;Le Molinette&quot;) di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Università degli Studi di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università &quot;Campus Bio-Medico&quot;, Rome</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia Vera</keyword>
  <keyword>GIVINOSTAT</keyword>
  <keyword>ITF2357</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Givinostat hydrochloride</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

